Last reviewed · How we verify
A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients. The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.
Details
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 22 |
| Start date | 2020-05-26 |
| Completion | 2021-03 |
Conditions
- NSCLC
Interventions
- Apatinib Mesylate, Gefitinib
Primary outcomes
- Cmax — 0-24 hours
Maximum Observed Plasma Concentration for apatinib - AUC0-τ — 0-24 hours
Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 hours
Countries
China